AbbVie Inc. (NYSE:ABBV) Shares Sold by Pacer Advisors Inc.

Pacer Advisors Inc. trimmed its holdings in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 1.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 388,002 shares of the company's stock after selling 3,913 shares during the period. Pacer Advisors Inc.'s holdings in AbbVie were worth $68,948,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Magnolia Capital Advisors LLC lifted its stake in shares of AbbVie by 89.5% in the 2nd quarter. Magnolia Capital Advisors LLC now owns 9,256 shares of the company's stock valued at $1,588,000 after purchasing an additional 4,371 shares during the period. Northwestern Mutual Wealth Management Co. boosted its position in AbbVie by 0.8% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 227,071 shares of the company's stock worth $38,948,000 after purchasing an additional 1,843 shares in the last quarter. Sunbelt Securities Inc. grew its holdings in AbbVie by 3.5% in the second quarter. Sunbelt Securities Inc. now owns 48,020 shares of the company's stock valued at $8,236,000 after purchasing an additional 1,622 shares during the period. William B. Walkup & Associates Inc. acquired a new position in shares of AbbVie during the 2nd quarter worth approximately $4,336,000. Finally, Invst LLC lifted its position in shares of AbbVie by 23.0% during the 2nd quarter. Invst LLC now owns 4,133 shares of the company's stock valued at $704,000 after buying an additional 774 shares in the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at AbbVie

In related news, SVP Kevin K. Buckbee sold 1,800 shares of the business's stock in a transaction on Monday, December 16th. The shares were sold at an average price of $172.24, for a total value of $310,032.00. Following the completion of the sale, the senior vice president now directly owns 6,983 shares of the company's stock, valued at $1,202,751.92. The trade was a 20.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.25% of the stock is owned by corporate insiders.

AbbVie Trading Down 1.1 %

Shares of NYSE ABBV traded down $2.02 during trading on Tuesday, reaching $174.88. The stock had a trading volume of 5,603,615 shares, compared to its average volume of 6,088,012. The business's 50-day moving average price is $176.05 and its 200-day moving average price is $184.94. AbbVie Inc. has a fifty-two week low of $153.58 and a fifty-two week high of $207.32. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.54 and a current ratio of 0.65. The company has a market cap of $309.04 billion, a P/E ratio of 60.72, a PEG ratio of 1.68 and a beta of 0.58.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $3.00 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.92 by $0.08. AbbVie had a net margin of 9.22% and a return on equity of 244.01%. The company had revenue of $14.46 billion for the quarter, compared to analyst estimates of $14.28 billion. During the same period in the prior year, the firm earned $2.95 earnings per share. The business's revenue for the quarter was up 3.8% compared to the same quarter last year. On average, equities research analysts predict that AbbVie Inc. will post 10.06 EPS for the current fiscal year.

AbbVie Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Investors of record on Wednesday, January 15th will be issued a $1.64 dividend. The ex-dividend date is Wednesday, January 15th. This is a positive change from AbbVie's previous quarterly dividend of $1.55. This represents a $6.56 dividend on an annualized basis and a yield of 3.75%. AbbVie's dividend payout ratio (DPR) is 227.78%.

Analyst Ratings Changes

A number of equities analysts have commented on the company. Guggenheim increased their target price on AbbVie from $212.00 to $221.00 and gave the company a "buy" rating in a report on Wednesday, November 6th. Wolfe Research began coverage on AbbVie in a report on Friday, November 15th. They issued an "outperform" rating and a $205.00 price objective on the stock. BMO Capital Markets dropped their target price on shares of AbbVie from $228.00 to $208.00 and set an "outperform" rating for the company in a report on Tuesday, November 12th. TD Cowen boosted their price target on shares of AbbVie from $195.00 to $225.00 and gave the stock a "buy" rating in a research report on Monday, October 7th. Finally, Bank of America reiterated a "neutral" rating and issued a $191.00 price objective on shares of AbbVie in a report on Tuesday, December 10th. Five analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $205.00.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.